View Exam | PowerPak

1. Which of the following statements regarding the role of CDK4/6 in ER+, HER2 negative breast cancer is true:

A. ER signaling down-regulates CDK4/6 activity B. Dysregulation of the cyclin D1:CDK4/6 axis appears to be a step in early breast cancer pathogenesis C. Downregulating CDK4/6 leads to cell division and growth in early breast cancer pathogenesis D. Resistance to endocrine blockers is not related to CDK4/6 signal potentiation

2. In clinical trials of CDK 4/6 inhibitors, what were the approximate hazard ratios for the study agent arm vs control arm?

A. 0.05 B. 0.25 C. 0.5 D. 0.75

3. The National Comprehensive Cancer Network (NCCN) recommends palbociclib plus letrozole or fulvestrant for first-line treatment of recurrent or stage IV ER+ breast cancer as a category 1 recommendation.

A. True B. False

4. At what point would a patient's ECG findings cause you to recommend permanent ribociclib discontinuation?

A. First occurrence of QTcF >490 msec B. Second occurrence of QTcF >480 msec C. QTcF >500 and ventricular tachycardia D. QTcF >500 msec on at least 2 separate ECGs within the same visit

5. According to recent study findings, which of the following is the most commonly reported motivator for treatment adherence?

A. Social support B. Good patient-provider relationship C. Knowledge about side effects D. Perception of illness

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following statements regarding the role of CDK4/6 in ER+, HER2 negative breast cancer is true:

2. In clinical trials of CDK 4/6 inhibitors, what were the approximate hazard ratios for the study agent arm vs control arm?

3. The National Comprehensive Cancer Network (NCCN) recommends palbociclib plus letrozole or fulvestrant for first-line treatment of recurrent or stage IV ER+ breast cancer as a category 1 recommendation.

4. At what point would a patient's ECG findings cause you to recommend permanent ribociclib discontinuation?

5. According to recent study findings, which of the following is the most commonly reported motivator for treatment adherence?

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following statements regarding the role of CDK4/6 in ER+, HER2 negative breast cancer is true:

2. In clinical trials of CDK 4/6 inhibitors, what were the approximate hazard ratios for the study agent arm vs control arm?

3. The National Comprehensive Cancer Network (NCCN) recommends palbociclib plus letrozole or fulvestrant for first-line treatment of recurrent or stage IV ER+ breast cancer as a category 1 recommendation.

4. At what point would a patient's ECG findings cause you to recommend permanent ribociclib discontinuation?

5. According to recent study findings, which of the following is the most commonly reported motivator for treatment adherence?

« Return to Activity

Customers who Purchased
this Activity also Purchased